Quarterly Report · 10-Q

Phathom Pharmaceuticals, Inc.

PHATNASDAQEQUITYCurrent

Quarterly Report

Filed Oct 29, 2026Accepted Oct 29, 2026, 7:05 AM EDTCIK 1783183Accession 0001193125-26-436961

Company context

Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Current securities

PHATNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

PHATHOM PHARMACEUTICALS, INC. · 10-Q · Filed 2026-10-29

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol: PHAT
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_67ec635d-1dab-40d3-8105-f3d242b0e3ac

Dimensions: Not supplied

Accession 000119312526436961 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.